Printed From:

Patient Profile

Meet Kathy, a Patient Whose RA Is Inadequately Controlled

Consider KEVZARA for patients like Kathy, whose moderate to severe RA is uncontrolled with current treatments. You can learn more about Kathy below, and please keep cases like hers top of mind when treating patients.

“I’ve been on a TNF inhibitor a while, but over the past 3 months
it’s been harder to keep up with my everyday activities.”

Kathy C.
Age 46, moderate to severe RA uncontrolled on a TNF inhibitor plus methotrexate

PHYSICAL FINDINGS/LABORATORY MEASUREMENTS:

  • Persistent tender (14) and swollen (10) joints

  • CRP level: 23 mg/L

  • Difficulty getting out of bed

  • Great difficulty with buttons

  • Struggling with pain

Hypothetical patient profile.
Models are used for representative
purposes only and are not actual patients with RA.

RA=rheumatoid arthritis; TNF=tumor necrosis factor; CRP=C-reactive protein.

Studies Showed Switching to a Different MOA Can Help Achieve Improved Patient Outcomes1,2

~30% of patients discontinued a TNF inhibitor due to lack of efficacy or intolerance3

Clinical trials demonstrated that patients with RA who switch to a biologic with an alternative MOA, instead of cycling to another TNF inhibitor, can achieve greater improvement in various measures.1,2,4-6*

TNF-IR patients who switched to a biologic with an alternative MOA saw greater improvement in1,2,4-6:

  • SIGN SYMPTOMS

    SIGNS & SYMPTOMS

  • DISEASE ACTIVITY

    DISEASE ACTIVITY

  • PHYSICAL FUNCTION

    PHYSICAL FUNCTION

The most recent ACR and EULAR RA treatment guidelines conditionally recommended switching MOA as a treatment option for TNF-IR patients7,8†

If treatment target of remission or low disease activity is not achieved in patients with moderate or high disease activity, despite the use of MTX or a TNF inhibitor:

  • Treat with a biologic agent with another mechanism of action or a second TNF inhibitor7,8

Patients not achieving remission or low disease activity with a TNF inhibitor treatment may benefit from a different MOA2,7,8

*Includes both prospective and real-world studies. Real-world studies did not include sarilumab.
2015 American College of Rheumatology Guidelines and 2016 EULAR Recommendations.

MOA=mechanism of action; TNF-IR=tumor necrosis factor-inadequate response or intolerant; ACR=American College of Rheumatology; EULAR=European League Against Rheumatism; MTX=methotrexate.

References: 1. Gottenberg JE, Brocq O, Perdriger A, et al. Non-TNF-targeted biologic vs a second anti-TNF drug to treat rheumatoid arthritis in patients with insufficient response to a first anti-TNF drug: a randomized clinical trial. JAMA. 2016;316(11):1172-1180. 2. Bonafede M, Curtis JR, McMorrow D, Mahajan P, Chen CI. Treatment effectiveness and treatment patterns among rheumatoid arthritis patients after switching from a tumor necrosis factor inhibitor to another medication. Clinicoecon Outcomes Res. 2016;8:707-715. 3. Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ; British Society for Rheumatology Biologics Register. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum. 2007;56(1):13-20. 4. Harrold LR, Reed GW, Magner R, Shewade A, John A, Greenberg JD, Kremer JM. Comparative effectiveness and safety of rituximab versus subsequent anti-tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti-tumor necrosis factor therapies in the United States Corrona registry. Arthritis Res Ther. 2015;17:256. 5. Emery P, Gottenberg JE, Rubbert-Roth A, et al. Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global observational, comparative effectiveness study. Ann Rheum Dis. 2015;74(6):974-984. 6. Finckh A, Ciurea A, Brulhart L, et al. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? Ann Rheum Dis. 2010;69(2):387-393. 7. Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68(1):1-26. 8. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):906-977.